These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Epigenetic deregulation of DNA repair and its potential for therapy. Hegi ME; Sciuscio D; Murat A; Levivier M; Stupp R Clin Cancer Res; 2009 Aug; 15(16):5026-31. PubMed ID: 19671858 [TBL] [Abstract][Full Text] [Related]
24. Array-based pharmacogenomics of molecular-targeted therapies in oncology. Sanoudou D; Mountzios G; Arvanitis DA; Pectasides D Pharmacogenomics J; 2012 Jun; 12(3):185-96. PubMed ID: 22249357 [TBL] [Abstract][Full Text] [Related]
25. Targeted and personalized therapy for cancer: theory and practice in China. Liu Q; Zhang X; Zeng Y Sci China Life Sci; 2011 Dec; 54(12):1081-4. PubMed ID: 22227898 [No Abstract] [Full Text] [Related]
26. [Personalized treatment of cancer: utopia or chance?]. Thiel E Dtsch Med Wochenschr; 2010 Sep; 135(38):1851. PubMed ID: 20842603 [No Abstract] [Full Text] [Related]
27. A rapidly growing number of therapeutics targeting tumor cell-intrinsic and -extrinsic processes is under development for individualized treatment of cancer patients. Giske CG; Jonkers J Drug Resist Updat; 2012; 15(1-2):1. PubMed ID: 22326647 [No Abstract] [Full Text] [Related]
28. Personalized-medicine trials on the rise. Benowitz S J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496 [No Abstract] [Full Text] [Related]
29. Refocusing the war on cancer: the critical role of personalized treatment. Potti A; Schilsky RL; Nevins JR Sci Transl Med; 2010 Apr; 2(28):28cm13. PubMed ID: 20410527 [TBL] [Abstract][Full Text] [Related]
30. The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor. Won JK; Yang HW; Shin SY; Lee JH; Heo WD; Cho KH J Mol Cell Biol; 2012 Jun; 4(3):153-63. PubMed ID: 22561840 [TBL] [Abstract][Full Text] [Related]
31. Modulation of apoptosis signaling for cancer therapy. Fulda S; Debatin KM Arch Immunol Ther Exp (Warsz); 2006; 54(3):173-5. PubMed ID: 16652217 [TBL] [Abstract][Full Text] [Related]
32. Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine. Picker A; Jackson DB Expert Rev Mol Diagn; 2011 Jul; 11(6):567-77. PubMed ID: 21745011 [TBL] [Abstract][Full Text] [Related]
33. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology]. Ludwig WD Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103 [TBL] [Abstract][Full Text] [Related]
34. [Future drug treatment against cancer viewed from current statistical data]. Nishiyama M Nihon Rinsho; 2015 Feb; 73 Suppl 2():16-22. PubMed ID: 25831718 [No Abstract] [Full Text] [Related]
35. Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis. Yauch RL; Settleman J Curr Opin Genet Dev; 2012 Feb; 22(1):45-9. PubMed ID: 22321987 [TBL] [Abstract][Full Text] [Related]
36. Cancer heterogeneity and signaling network-based drug target. Roukos DH Pharmacogenomics; 2013 Aug; 14(11):1243-6. PubMed ID: 23930670 [No Abstract] [Full Text] [Related]
37. Mechanisms of drug inhibition of signalling molecules. Sebolt-Leopold JS; English JM Nature; 2006 May; 441(7092):457-62. PubMed ID: 16724058 [TBL] [Abstract][Full Text] [Related]
38. In search of novel molecular targets in cancer: the diacyglycerol pathways. Lorenzo PS Hawaii Med J; 2004 Oct; 63(10):318-9, 321. PubMed ID: 15570721 [No Abstract] [Full Text] [Related]
39. Growth industry. Lewis R Nature; 2004 Mar; 428(6980):348-9. PubMed ID: 15029202 [No Abstract] [Full Text] [Related]